Richard (Rick) Mills
Ahead of the Herd
Page 1 of 3
As a general rule, the most successful man in life is the man who has the best information
Aubrey de Grey a biomedical gerontologist, predicted that the first person to live to a thousand has already been born. According to de Grey the key may lie in the field of regenerative medicine.
The Webster dictionary defines biological regeneration as “the restoration or the growth by an organism of organ or tissue, that has been lost, removed or injured.”
Dr. William Haseltine CEO of Human Genome Sciences, believes thatregenerative medicine is about assisting the body to heal itself. Dr. Haseltine coined the term "regenerative medicine," to describe the expected medical revolution that, in his view, could lead to human immortality.
Stanford University’s Dr. Helen Blau wrote that the goal of regenerative medicine is to restore form and function to damaged tissues.
I think we can decide for ourselves that regenerative medicine means replacing, engineering or regenerating human cells, tissues or organs with the goal being to re-establish normality for conditions that currently are beyond repair.
“Cell therapy uses living cells as treatments. Its potential to cure or transform serious medical conditions lies in the nature of cells and their ability to interact with the body at levels of complexity many orders of magnitude greater than conventional drugs. Regenerative medicine is focused on the regeneration of tissues and organs using all the different therapeutic platform technologies available: small molecule drugs, biologics, medical devices and cells. Stem cell technologies, cell therapy and regenerative medicine are closely entwined and will ultimately transform the practice of medicine from today’s model of continual interventions to single
treatment cures.” Following Through: Realizing the Promise of Stem Cells, KPMG
Stem cells are the foundation for every organ and tissue in the body.
Stem cell research is leading the way for the hugely transformative and disruptive potential of regenerative medicine.
All stem cells can self-renew – clone themselves - and differentiate, meaning they can develop into more specialized cells.
Embryonic stem cells
Embryonic stem cells are obtained from the inner cell mass of the blastocyst, a mainly hollow ball of cells that, in humans, forms three to five days after an egg cell is fertilized by a sperm. Embryonic stem cells are pluripotent, meaning they can give rise to every cell type in the fully formed body, but not the placenta and umbilical cord.
Tissue-specific stem cells
Tissue-specific stem cells (also referred to as somatic or adult stem cells) are more specialized than embryonic stem cells. Typically, these stem cells can generate different cell types for the specific tissue or organ in which they live.
Induced pluripotent stem cells
Induced pluripotent stem (iPS) cells are cells that have been engineered in the lab by converting tissue-specific (somatic/adult) cells, such as skin cells, into cells that behave like embryonic stem cells.
Treatments include both in vivo and in vitro procedures:
- In vivo - studies and trials performed inside the living body in order to stimulate previously irreparable organs to heal themselves
- In vitro - treatments are applied to the body through implantation of a therapy studied inside the laboratory
Sernova Corp TSX.V; SEOVF – SVA
For the past 25 years, scientific laboratories around the world, with specialty trained experts in cell technologies, were learning the processes for how the body turns starting generalized stem cells into the mature functional cells.
Recent scientific advances have turned these scientists towards developing therapeutic cells to treat diseases such as Diabetes. If successful these technologies have the ability to treat millions of patients unlike the currently available donor cells.
The ultimate goal of regenerative medicine for technologies that produce proteins or hormones as therapeutics, is to develop an unlimited supply of safe and efficacious therapeutic stem cell derived therapeutic cells placed, in a simple procedure, within the body in a cell friendly and retrievable medical device, while being protected from immune system attack.
When the time came, Sernova Corp was determined to be in the forefront of such technologies with strong proof of concept on their therapeutic device with donor therapeutic cells within.
Knowing the importance of these developments, back in 2009, Sernova began working on, and patented, a proprietary, scalable, implantable medical device, their Cell Pouch™ that creates a natural environment for the survival and function of therapeutic cells. The unique aspects of Sernova’s Cell Pouch™ platform is that device is scalable, and the cells within the device are intimately associated with the critical tissue matrix and microvessels that keep cells alive and functioning. For those cells which require protection from the immune system, local cellular immune protection enables the cells to remain in intimate association with this tissue matrix and microvessels while preventing immune cells access to the therapeutic cells. These make Sernova’s technologies ideal for multiple types of cells that produce therapeutic factors.
The following examples are two diseases that regenerative medicine for technologies that produce proteins or hormones as therapeutics has the potential to cure and what the current standard of care looks like.